MedTrace Logo

18F-Fluorodeoxyglucose Positron Emission Tomography in Oncology and Neurology

NCT01180751 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2013-08-15

No results posted yet for this study

Summary

This clinical trial is being conducted to study the use of a radioactive glucose tracer as an imaging test \[Positron Emission Tomography (PET)scan\] in adults who have or are suspected of having cancer and in another group of adults to assess for neurologic conditions.

Conditions

Interventions

RADIATION

[18F]-Fluorodeoxyglucose

With each Positron Emission Tomography/Computed Tomography (PET/CT)scan an intravenous administration of radioactive glucose (FDG)is given. This is a weight dependent dosage.

Sponsors & Collaborators

  • Winnipeg Regional Health Authority

    collaborator OTHER

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Daniel P Levin, BSc,MD,FRCPC · Winnipeg Regional Health Authority

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2013-06-30
Completion
2013-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01180751 on ClinicalTrials.gov